AR045016A1 - Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades. - Google Patents
Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades.Info
- Publication number
- AR045016A1 AR045016A1 ARP040102366A ARP040102366A AR045016A1 AR 045016 A1 AR045016 A1 AR 045016A1 AR P040102366 A ARP040102366 A AR P040102366A AR P040102366 A ARP040102366 A AR P040102366A AR 045016 A1 AR045016 A1 AR 045016A1
- Authority
- AR
- Argentina
- Prior art keywords
- complement cascade
- metilsulfaniltiofen
- carbamimidoi
- sulfonil
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Inhibidores conjugados de la cascada de complemento, y a un método para tratar a un paciente utilizando un inhibidor conjugado de la cascada de complemento. Reivindicación 1: Una composición que comprende un inhibidor conjugado del complemento. Reivindicación 2: La composición de la reivindicación 1 que presenta un grupo de fórmulas: (D-L)n-P o D-Ln-Pn', en los cuales: D se selecciona independientemente en cada aparición de compuestos que son inhibidores de la cascada de complemento; L es un grupo conector opcional (en cada aparición) seleccionado independientemente en cada aparición; n es 1, 2, 3, 4, 5 ó 6; n' es 1, 2, 3 ó 4; y P se selecciona independientemente en cada aparición de compuestos que mejoran las propiedades farmacocinéticas de D.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48485403P | 2003-07-03 | 2003-07-03 | |
US57137404P | 2004-05-14 | 2004-05-14 | |
US10/869,430 US7482376B2 (en) | 2003-07-03 | 2004-06-16 | Conjugated complement cascade inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045016A1 true AR045016A1 (es) | 2005-10-12 |
Family
ID=33556451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102366A AR045016A1 (es) | 2003-07-03 | 2004-07-05 | Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades. |
Country Status (14)
Country | Link |
---|---|
US (1) | US7482376B2 (es) |
EP (1) | EP1644046A2 (es) |
JP (1) | JP2007535474A (es) |
KR (1) | KR20060032994A (es) |
AR (1) | AR045016A1 (es) |
AU (1) | AU2004253474B2 (es) |
BR (1) | BRPI0412298A (es) |
CA (1) | CA2530480A1 (es) |
HR (1) | HRP20060007A2 (es) |
MX (1) | MXPA06000277A (es) |
MY (1) | MY138732A (es) |
NZ (1) | NZ544407A (es) |
TW (1) | TW200510397A (es) |
WO (1) | WO2005002627A2 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083786B2 (en) * | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
HUE024996T2 (en) | 2003-05-12 | 2016-01-28 | Helion Biotech Aps | Anti-MASP-2 antibodies |
US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
GB0412966D0 (en) * | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
PL1753456T3 (pl) * | 2004-06-10 | 2017-01-31 | Omeros Corporation | Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2 |
EP1937802A4 (en) * | 2005-09-20 | 2009-06-10 | London Health Sci Ct Res Inc | USE OF SMALL INTERFERING RNA IN ORGAN CONSERVATION / REPERFUSION SOLUTIONS |
EP2061810B1 (en) * | 2006-09-05 | 2014-11-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
PL2698166T3 (pl) | 2006-10-10 | 2016-03-31 | Regenesance B V | Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów |
BR112012008970A2 (pt) * | 2009-10-16 | 2019-12-10 | Omeros Corp | uso de uma composição, e, composição |
US8993614B2 (en) | 2012-03-15 | 2015-03-31 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
EP3722320A3 (en) * | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
JP6543572B2 (ja) | 2012-11-02 | 2019-07-10 | バイオベラティブ・ユーエスエイ・インコーポレイテッド | 抗補体C1s抗体とそれらの用途 |
RS63956B1 (sr) | 2015-04-06 | 2023-02-28 | Bioverativ Usa Inc | Humanizovana anti-c1s antitela i metode njihove upotrebe |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
US10699448B2 (en) | 2017-06-29 | 2020-06-30 | Covidien Lp | System and method for identifying, marking and navigating to a target using real time two dimensional fluoroscopic data |
US10893842B2 (en) | 2018-02-08 | 2021-01-19 | Covidien Lp | System and method for pose estimation of an imaging device and for determining the location of a medical device with respect to a target |
BR112021004263A2 (pt) | 2018-09-06 | 2021-05-25 | Achillion Pharmaceuticals, Inc. | formas mórficas de danicopano |
MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
US11357593B2 (en) | 2019-01-10 | 2022-06-14 | Covidien Lp | Endoscopic imaging with augmented parallax |
MX2021011507A (es) * | 2019-03-22 | 2021-12-15 | Achillion Pharmaceuticals Inc | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. |
JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Masp-2阻害剤および使用方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
US5180569A (en) | 1990-12-31 | 1993-01-19 | Phosphate Engineering And Construction Company | Process for the production of phosphoric acid and hydrogen fluoride from phosphate rock and fluosilicic acid |
SG63617A1 (en) | 1991-01-18 | 1999-03-30 | Amgen Boulder Inc | Methods for treating tumar necrosis factor mediated diseases |
SG47099A1 (en) | 1991-03-15 | 1998-03-20 | Amgen Boulder Inc | Pegylation of polypeptides |
US20030171292A1 (en) | 1992-06-01 | 2003-09-11 | Creasey Abla A. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
US6063764A (en) | 1992-06-01 | 2000-05-16 | Washington University & Chiron Corp. | Method for using lipoprotein associated coagulation inhibitor to treat sepsis |
JPH08268912A (ja) | 1995-03-31 | 1996-10-15 | Green Cross Corp:The | 補体活性化の抑制剤 |
AU1404597A (en) | 1995-12-21 | 1997-07-17 | Procur Ab | Galactopyranosides and their use |
JP3092531B2 (ja) | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法 |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
ATE223408T1 (de) * | 1998-02-09 | 2002-09-15 | Dimensional Pharm Inc | Heteroaryl-amidinen,-methylamidinen und - guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren |
CZ20012858A3 (cs) * | 1999-02-09 | 2002-05-15 | 3-Dimensional Pharmaceuticals, Inc. | Heteroarylamidiny, methylamidininy a guanidiny jako inhibitory proteasy |
WO2000047194A2 (en) | 1999-02-09 | 2000-08-17 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
MXPA02006216A (es) | 1999-12-22 | 2004-02-26 | Nektar Therapeutics Al Corp | Derivados estericamente impedidos de polimeros solubles en agua. |
AU2001257577A1 (en) | 2000-02-28 | 2001-09-03 | Shearwater Corporation | Water-soluble polymer conjugates of artelinic acid |
US7071299B2 (en) | 2000-06-21 | 2006-07-04 | Zymogenetics, Inc. | Peptide and polypeptide inhibitors of complement C1s |
TWI246524B (en) | 2001-01-19 | 2006-01-01 | Shearwater Corp | Multi-arm block copolymers as drug delivery vehicles |
EA009125B1 (ru) | 2001-05-16 | 2007-10-26 | Йеда Рисерч Энд Дивелопмент Ко., Лтд. | Применение ингибиторов il-18 для лечения и/или предупреждения заболеваний, характерных для синдрома системной воспалительной реакции |
JP4123856B2 (ja) | 2001-07-31 | 2008-07-23 | 日油株式会社 | 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法 |
EP2939696B1 (en) | 2001-10-18 | 2016-03-09 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
US20030143185A1 (en) | 2001-10-29 | 2003-07-31 | Shearwater Corporation | Polymer conjugates of protein kinase C inhibitors |
CA2464346A1 (en) | 2001-10-30 | 2003-05-08 | Nektar Therapeutics Al, Corporation | Water-soluble polymer conjugates of retinoic acid |
BR0311419A (pt) * | 2002-05-28 | 2005-04-05 | Dimensional Pharm Inc | Amidinas de tiofeno suas composições e métodos de tratamento de doenças e condições mediadas por complemento |
US7482376B2 (en) * | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
-
2004
- 2004-06-16 US US10/869,430 patent/US7482376B2/en not_active Expired - Fee Related
- 2004-06-18 EP EP04776732A patent/EP1644046A2/en not_active Withdrawn
- 2004-06-18 WO PCT/US2004/019457 patent/WO2005002627A2/en active Application Filing
- 2004-06-18 CA CA002530480A patent/CA2530480A1/en not_active Abandoned
- 2004-06-18 BR BRPI0412298-4A patent/BRPI0412298A/pt not_active IP Right Cessation
- 2004-06-18 JP JP2006518654A patent/JP2007535474A/ja not_active Ceased
- 2004-06-18 KR KR1020067000196A patent/KR20060032994A/ko not_active Application Discontinuation
- 2004-06-18 AU AU2004253474A patent/AU2004253474B2/en not_active Ceased
- 2004-06-18 NZ NZ544407A patent/NZ544407A/en unknown
- 2004-06-18 MX MXPA06000277A patent/MXPA06000277A/es unknown
- 2004-06-30 MY MYPI20042599A patent/MY138732A/en unknown
- 2004-06-30 TW TW093119851A patent/TW200510397A/zh unknown
- 2004-07-05 AR ARP040102366A patent/AR045016A1/es not_active Application Discontinuation
-
2006
- 2006-01-03 HR HR20060007A patent/HRP20060007A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004253474B2 (en) | 2010-12-23 |
NZ544407A (en) | 2009-03-31 |
WO2005002627A2 (en) | 2005-01-13 |
HRP20060007A2 (en) | 2006-08-31 |
WO2005002627A3 (en) | 2005-07-28 |
JP2007535474A (ja) | 2007-12-06 |
MXPA06000277A (es) | 2006-07-03 |
MY138732A (en) | 2009-07-31 |
US7482376B2 (en) | 2009-01-27 |
AU2004253474A1 (en) | 2005-01-13 |
TW200510397A (en) | 2005-03-16 |
CA2530480A1 (en) | 2005-01-13 |
EP1644046A2 (en) | 2006-04-12 |
BRPI0412298A (pt) | 2006-09-19 |
US20050004031A1 (en) | 2005-01-06 |
KR20060032994A (ko) | 2006-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045016A1 (es) | Derivados de 5-carbamimidoi-2-metilsulfaniltiofen-3-sulfonil como inhibidores conjugados de la cascada de complemento y su uso en el tratamiento de enfermedades. | |
CY1115286T1 (el) | Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson | |
ECSP034750A (es) | Derivados de espirociclicos nuevos y su uso como inhibidores de fosfodiesterasa-7 | |
EA200601648A1 (ru) | Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы | |
ATE499109T1 (de) | Zusammensetzung zur proteasomhemmung | |
AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
UY26981A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
CY1105080T1 (el) | Ενωσεις θειενοπυρρολυλιου και φουρανοπυρρολυλιου και η χρηση τους ως συνδετες η4 υποδοχεα ισταμινης | |
PE20020521A1 (es) | Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas | |
DK1525177T3 (da) | Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf | |
HN2001000244A (es) | Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas. | |
BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
UY27774A1 (es) | Inhibidores de metaloproteinas de triaril-oxi-aril-espiropirimidina-2,4,6-triona | |
UY28098A1 (es) | Derivados de anilinopirazol útiles en el tratamiento de la diabetes | |
RU2009149684A (ru) | Комбинации вазоактивных веществ с эстрогенами и их применение для лечения сексуальных дисфункций у женщин | |
SE0002934D0 (sv) | New aporphine esters and in their use in therapy | |
TR200201250T2 (tr) | Hidroksieikosatetraenoat tuzları, bileşimleri ve bunların göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri. | |
BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) | |
DOP2003000621A (es) | Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa | |
UY27018A1 (es) | Derivados de la pirimidina | |
SE0003476D0 (sv) | Compounds | |
BRPI0411324A (pt) | composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes | |
ATE417856T1 (de) | Motilidverbindungen | |
NO20051261L (no) | Morfin-6-glukuronidsalt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |